.
DeepHealth (Nasdaq: RDNT) unveiled an expanded portfolio of imaging informatics and clinical AI solutions at the Radiological Society of North America (RSNA) 2025 conference on November 30, 2025. The launch introduces integrated capabilities across the Diagnostic Suite, TechLive, Operations Suite and disease‑focused Clinical AI suites (Breast, Thyroid, Neuro, Chest, Prostate) that run on DeepHealth OS, a cloud‑native platform designed to unify imaging workflows, reporting and AI orchestration.
Key performance indicators disclosed include more than 400 scanners linked to TechLive, a 42 percent reduction in magnetic‑resonance (MR) room closures, support for over 10 million mammograms each year, a Nature Health analysis showing a 21 percent uplift in breast‑cancer detection among 579,000 women, deployments at over 200 sites for the Thyroid Suite, and adoption by more than 2,000 customers and 5,000 radiologists.
Positive
- TechLive connects over 400 scanners to a remote‑management hub
- TechLive associated with a 42 percent decline in MR room closures
- Breast Suite supports more than 10 million mammograms annually
- Nature Health study documents a 21 percent increase in breast‑cancer detection
- Thyroid Suite deployed across more than 200 RadNet sites
- Portfolio used by over 2,000 customers and 5,000 radiologists
Negative
- Chest Suite applications remain 510(k) pending in the United States, limiting domestic availability
- Prostate Suite lesion‑detection and classification are also 510(k) pending
Insights
DeepHealth expands its integrated AI imaging suites, secures multiple FDA clearances, and scales real‑world deployments, substantially widening product reach.
DeepHealth’s strategy hinges on DeepHealth OS, a cloud‑first operating system that hosts modular suites for Breast, Thyroid, Neuro, Chest and Prostate imaging. The company claims regulatory clearances for most applications and highlights plug‑and‑play AI integration through AI Studio, which can ingest more than 140 algorithms from dozens of vendors. Quantitative metrics underscore the commercial traction: a 42 percent drop in MR downtime, support for over 10 million mammograms per year, and a 21 percent lift in breast‑cancer detection in a large‑scale U.S. cohort. The Thyroid Suite is active at more than 200 sites with a 94 percent acceptance rate for AI‑generated measurements.
Key risks revolve around pending 510(k) submissions for Chest and Prostate suites, the complexity of integrating with heterogeneous vendor ecosystems, and the migration path for existing RIS customers to the new Operations Suite. Near‑term milestones to watch include the FDA review outcomes for the pending applications, the pace of customer migration to DeepHealth OS, and the impact of the announced partnership with GE HealthCare on global distribution.
Operational suites and remote‑scanning tools aim to reduce throughput friction and administrative burden across imaging networks.
The Operations Suite consolidates scheduling, registration, billing, analytics and patient engagement into a single cloud or hybrid environment. Early deployments at RadNet sites report measurable efficiency gains, most notably the connection of more than 400 scanners to TechLive and a 42 percent reduction in MR room closures. These outcomes suggest that remote‑management capabilities can expand capacity without the need for additional hardware.
Implementation challenges include the migration of legacy RIS infrastructures, ensuring data security in hybrid cloud configurations, and maintaining AI governance as algorithmic models evolve. Tracking adoption rates for the Operations Suite, the effectiveness of AI drift‑monitoring in AI Studio, and the timing of the pending U.S. clearances for Chest and Prostate suites will be critical indicators of the platform’s long‑term viability.
Company expands portfolio of AI‑powered clinical and operational solutions, delivering proven impact at scale and empowering breakthroughs in care through imaging.
CHICAGO, Nov. 30, 2025 (GLOBE NEWSWIRE) – DeepHealth, a global leader in AI‑driven health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), announced an expanded suite of imaging informatics and clinical AI solutions at RSNA 2025. The rollout spans disease detection, remote scanning, image management, workflow automation and AI orchestration, all built on DeepHealth OS.
“AI‑enabled imaging can drive proactive, connected and more equitable care at global scale,” said Kees Wesdorp, President and CEO of DeepHealth. “By unifying clinical and operational intelligence into a cloud‑native platform, we accelerate adoption, expand patient access and improve operational efficiency. That’s how we empower breakthroughs in care through imaging.”
DeepHealth’s integrated portfolio addresses three persistent industry challenges: fragmented patient engagement, workforce strain, and inconsistent clinical outcomes.
Unifying the Imaging Experience
- Diagnostic Suite – A cloud‑first enterprise image management and interpretation platform that now includes rapid data migration, ultra‑fast streaming, AI‑augmented reporting, advanced visualization and enterprise‑wide AI orchestration. Recent acquisition of CIMAR UK adds European cloud‑image management capabilities.
- TechLive – A vendor‑agnostic remote‑imaging solution with 510(k) clearance that extends expert oversight across MR, ultrasound, CT and PET/CT. More than 400 scanners are connected, delivering a 42 percent reduction in MR room closures. TechLive can be purchased standalone or via a collaboration with GE HealthCare for ultrasound integration.
- Operations Suite – A cloud‑first suite that converges scheduling, registration, billing, analytics and patient communication. New AI‑driven patient‑engagement tools automate routine tasks, reduce administrative load and improve throughput. Early deployments report measurable efficiency gains.
Advancing Population Health with Clinical AI
- Breast Suite – An FDA‑cleared, end‑to‑end breast‑cancer detection workflow that includes risk assessment, density analysis and emerging arterial calcification metrics. The suite processes over 10 million mammograms annually. A Nature Health analysis of 579,000 women showed a 21 percent increase in cancer detection, with consistent benefits across dense‑breast and diverse populations.
- Thyroid Suite – AI‑powered tools that automate nodule detection, measurement and characterization across all major ultrasound manufacturers. Deployed at more than 200 RadNet sites, AI measurements were accepted without correction in over 94 percent of 4,070 evaluated nodules.
- Neuro Suite – FDA‑cleared applications for white‑matter hyperintensity segmentation (Brain Health) and volumetric brain‑age estimation (Brain Age), providing longitudinal tracking of neurodegenerative change.
- Chest Suite – Pulmonary nodule detection, characterization and volumetric quantification, cleared in Europe and the UK. U.S. clearance is pending (510(k)). The suite underpins large‑scale lung‑cancer screening programs, including NHS England’s initiative that now captures 76 percent of cancers at early, treatable stages.
- Prostate Suite – A next‑generation workflow that integrates lesion detection, risk classification, gland segmentation and PI‑RADS‑compliant reporting. FDA clearance is pending; the suite is already supporting the TRANSFORM prostate‑screening trial in the United Kingdom.
- AI Studio – A unified AI orchestration layer that can host over 140 algorithms from more than 75 vendors, providing governance tools for performance monitoring, drift detection and compliance.
All solutions run on DeepHealth OS™, a cloud‑native operating system that delivers role‑based experiences, seamless data access and unified security across on‑premises, private‑cloud or public‑cloud deployments. This architecture simplifies IT operations, reduces infrastructure costs and accelerates time‑to‑value for health systems.
DeepHealth partners with leading OEMs, cloud providers and AI vendors to eliminate fragmentation and deliver a connected, end‑to‑end imaging experience. More than 2,000 customers and over 5,000 radiologists worldwide already rely on DeepHealth solutions to improve diagnostic accuracy, increase throughput and enable earlier disease detection.
FAQ
What did DeepHealth announce at RSNA 2025?
DeepHealth unveiled an expanded Imaging OS, Diagnostic Suite, Operations Suite and Clinical AI suites on November 30, 2025, aimed at scaling AI‑powered imaging across its network.
How many scanners are connected to TechLive and what is the impact?
TechLive is linked to more than 400 scanners and is reported to reduce MR room closures by 42 percent.
What evidence supports the effectiveness of the Breast Suite?
A Nature Health analysis covering over 579,000 women shows a 21 percent increase in breast‑cancer detection using Breast Suite applications.
Is the Chest Suite available in the United States?
Chest Suite applications are cleared in Europe and the UK but are currently pending U.S. 510(k) clearance.
How widely is the Thyroid Suite deployed?
The Thyroid Suite is active at more than 200 RadNet sites, with AI measurements accepted in over 94 percent of evaluated nodules.
What is DeepHealth OS and why is it important?
DeepHealth OS is a cloud‑native platform that unifies imaging data, AI orchestration and workflow tools, simplifying deployment and enabling enterprise‑wide scaling.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/13803.html
